A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID, cc-5013) (IND 73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 15 Dec 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700028982,700057042, 70059082) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.